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endometrial carcinoma and ovarian carcinoma; indeed, endometrial
carcinoma is seen as commonly as CRC in these individuals and is
often the sentinel malignancy. In contrast, predisposition to cervical
cancer is not a feature of LS (Barrow et al., 2013). There have been
only occasional cases of cervical cancer reported in the literature in
patients with LS; one patient with a germline-mutation in MSH2, in
which the tumour was immunohistochemically deﬁcient for MSH2
and MSH6 with high levels of MSI (Mongiat-Artus et al., 2006) and
the other with the Muir–Torre variant of LS, where individuals havewas described as an adenocarcinoma with focal serous papillary
Introduction
Lynch syndrome (LS), also known as hereditary non-polyposis
colorectal cancer (HNPCC), is an uncommon, but not rare, autosomal
dominant familial cancer syndrome (Barrow et al., 2013). This condition
predisposes individuals to colorectal carcinoma (CRC) as well as various
extra-colonic tumours including cancer of the endometrium, ovaries,
small bowel, stomach and urothelium (Barrow et al., 2013).
Tumours arise as a result of inactivating mutations in genes
encoding essential proteins in the DNA mismatch repair (MMR)
pathway (Barrow et al., 2013; Masuda et al., 2011). This pathway is
principally involved in the repair of replication errors, such as base
mismatches and small insertions or deletions, in highly repetitive base
sequences known as microsatellites (Masuda et al., 2011). Accumula-
tion of these mutations, in genes involved in carcinogenesis, predis-
poses cellular malignant transformation; hence individuals with LS
have an increased incidence of speciﬁc tumours (Barrow et al., 2013;
Masuda et al., 2011). Four human MMR genes have been implicated in
this condition; MLH1, MSH2, MSH6 and PSM2 (Masuda et al., 2011).
Mutations icbun MLH1 and MSH2 account for approximately 90% of
all LS cases (Barrow et al., 2013)., 5th Floor, St Mary's Hospital,
(R.J. Edmondson).
pen access article under the CC BY-Ndefects in either MSH2 or MLH1 (Mongiat-Artus et al., 2006; Nair
et al., 2012). In the ﬁrst case, there was nomention of the tumour mor-
phology (Mongiat-Artus et al., 2006) while in the second the neoplasm
features (Nair et al., 2012). In the second case, there was no mention
of testing the tumour for MSI or undertaking immunohistochemistry
for mismatch repair proteins.
In this case report, we describe a case of gastric-type cervical
adenocarcinoma in a patient with LS secondary to an MSH6 muta-
tion. We discuss the possibility that LS may be associated with rare
non-HPV related cervical adenocarcinomas.
Case report
A 50 year-old female underwent a supracervical abdominal
hysterectomy and bilateral salpingo-oophorectomy as a prophylactic
procedure for previously diagnosed LS. The patient was asymptomatic
at the time of surgery.
Eight years previously, a family history of early onset colonic cancer
led to genetic testing,which subsequently revealed a germlinemutation
in theMSH6 gene on chromosome2, consistentwith the diagnosis of LS.
The patient had no history of malignancy, with the last colonoscopy for
colonic cancer surveillance undertaken 2 years ago and reported as
normal. Cervical smears were up-to-date and normal with no evidence
of a squamous or glandular abnormality.
Gross pathological examination revealed no abnormality in the
uterus, cervix, ovaries or fallopian tubes. The entire endometrium and
cervix were examined histologically. Focal atypical endometrial hy-
perplasiawas identiﬁedwith no evidence of endometrial adenocarcino-
ma. The cervix was incompletely excised without representation of theC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Adenocarcinoma composed of cells with abundant clear or eosinophilic cytoplasm and with an associated pronounced inﬂammatory inﬁltrate.
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arate foci of abnormal glandular proliferation were present. Thesemea-
sured 8 mm and 3 mm in their maximum horizontal dimension and
both had a depth of invasion of 1.5 mm. Both areas comprised moder-
ately differentiated adenocarcinomas composed of tumour cells with
atypical nuclei, clear cytoplasm and prominent cell membranes. There
was an associated brisk inﬂammatory inﬁltrate, mainly consisting of
lymphocytes (Fig. 1). Immunohistochemically, both foci were largely
negative for p16 andwere negative for oestrogen receptor (ER), proges-
terone receptor (PR) and carcinoembryonic antigen (CEA). Both foci
were clear of the margins and there was no lymphovascular invasion.
Linear array HPV genotyping (Roche Molecular Diagnostics,
Pleasanton, California, USA) was performed on parafﬁn blocks of
the areas containing the abnormal cervical glandular proliferation.
Linear array HPV genotyping involves PCR ampliﬁcation of target
DNA followed by hybridization for the detection of 37 HPV types; 18
high risk types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66,
68, 73, 82) and 19 low risk types (6, 11, 40, 42, 54,55, 61, 62, 64, 67,
69, 70, 71, 72, 81, 83, 84, IS39, CP108). HPV testing was negative.
Given the morphology, immunohistochemistry and the absence
of HPV, a diagnosis of primary cervical gastric-type adenocarcinoma
was made. Immunohistochemistry for mismatch repair proteins was
performed and this demonstrated normal nuclear staining with MLH1,
PMS2 and MSH2. MSH6 was difﬁcult to interpret due to cytoplasmic
immunoreactivity but there was loss of nuclear staining with a positive
internal control in the form of nuclear staining of some lymphoid and
stromal cells.
The ovaries and fallopian tubes showed no histological abnormality.
Following the histological results, the residual cervix was assessed
by examination under anaesthesia (EUA), cystoscopy and pelvic
MRI scan. No cervical abnormality was detected on MRI and the
3 cm cervical stump was mobile on EUA, with no evidence of
parametrial, bladder or rectal involvement. The tumour was provision-
ally staged as FIGO 1B1 (based on the histological measurements). Both
surgery, in the form of a radical hysterectomy with lymphadenectomy,
and chemoradiationwere considered as equally effective treatment op-
tions (Landoni et al., 1997). After discussion with the patient, laparoto-
my with excision of the cervical stump and vaginal cuff with bilateralpelvic node dissection was undertaken along with omentectomy,
given the high rate of intraabdominal dissemination described with
cervical gastric-type adenocarcinoma (to be discussed later) (Kojima
et al., 2007). There was no evidence of macroscopic disease at laparoto-
my and histological assessment of all resected specimens, including the
cervical stump, parametria, vaginal cuff, omentum, infundibular pelvic
ligaments, pelvic nodes and common iliac nodes, was unremarkable
with no evidence of residual or metastatic adenocarcinoma.
No adjuvant therapy was recommended and routine follow was
arranged with the surgical gynaecological team. She has now been in
follow up for 18 months with no evidence of disease.
Discussion
We report a rare case of gastric-type adenocarcinomaof the cervix in
a patient with LS secondary to a germline mutation in the MSH6 MMR
gene. As this patient had coexisting endometrial atypical hyperplasia,
initially it was considered whether the cervical glandular proliferation
could have represented spread from the endometrium. However,
a thorough histological examination of the entire endometrium
was performed and no evidence of invasive endometrial carcinoma
was identiﬁed. Moreover, the morphology and immunophenotype
(hormone receptor negative) were not that of an endometrioid
adenocarcinoma of the endometrium.
The morphological features were in keeping with a cervical gastric-
type adenocarcinoma. This subtype is an uncommon variant of primary
cervical adenocarcinoma which exhibits gastric differentiation (on the
basis of mucin histochemistry and immunohistochemistry) and, in
contrast to the majority of cervical cancers, is not associated with HPV
infection. Histologically, gastric type adenocarcinoma is characterised
by tumour cells with atypical nuclei and abundant clear or eosinophilic
cytoplasm, typically with distinct cell borders. There is sometimes a
marked associated inﬂammatory inﬁltrate, including lymphocytes,
neutrophils and eosinophils. p16 is usually negative or only focally
positive, in contrast to HPV associated adenocarcinomas where diffuse
positive staining is seen. Although the clinical features have not been
extensively studied, it is thought that cervical gastric type adenocar-
cinoma is associated with aggressive behaviour and a poor prognosis,
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semination (Kojima et al., 2007). Kojima et al. found that gastric type
adenocarcinomas had a 5 year disease free survival of 30% com-
pared to 74% for usual endocervical-type adenocarcinomas
(Kojima et al., 2007).
In this case, the tumour exhibited loss of nuclear expression ofMSH6
thus supporting the association of this adenocarcinoma to the patient's
known MSH6 germline mutation, rather than representing a sporadic
tumour. This is somewhat unusual as cervical adenocarcinoma is not
one of the tumours typically considered to be associated with LS.
Indeed, a recent study undertaken by Mills et al. demonstrated intact
MMR protein in 60 cervical adenocarcinomas (Mills et al., 2012).
The mutations in the MMR genes vary between LS patients and are
often family-speciﬁc. It is plausible that certain mutations confer a sus-
ceptibility to the development of unusual tumours. Indeed, this theory
has been suggested in a separate case report describing an unusual
spectrum of tumours in a family of patients with LS (Yu et al., 2009).
Another recent study described the occurrence of four unusual tumours
in patients with LS, suggesting that the spectrum of tumours associated
with this syndrome may be wider than is currently appreciated
(Karamurzin et al., 2012). Germane to the current case, it is interesting
that LS associated endometrial carcinomas have been reported to more
frequently having a lower uterine segment (LUS) location (Westin,
2008). Given that non-HPV related cervical adenocarcinomas, including
gastric-type, may arise proximal to the transformation zone and extend
to involve the LUS, it is possible that some of the LUS carcinomas
reported in patients with LS represent non-HPV related cervical
adenocarcinomas.
Our usual practicewould be to always carry out a total hysterectomy
for patients with LS but this patient was initially treated at a referring
hospital by a non gynaecological oncology surgeon and thus underwent
a supracervical hysterectomy.
This case highlights the fact that unusual tumour typesmay occur in
patients with LS. MMR immunohistochemistry is a useful screening tool
in unusual tumours when LS is suspected and loss of immunoreactivitywith 1 ormore of theMMR proteinsmay direct further investigations to
conﬁrm or exclude LS.MMR immunohistochemistry also has the advan-
tage of suggestingwhichMMR gene is likely to be mutated and thus fo-
cusing further molecular tests.
Conclusion
We describe an unusual case of a LS associated cervical gastric-type
adenocarcinoma. Further study of unusual non-HPV related variants of
cervical adenocarcinoma arewarranted to ascertain if there is an associ-
ation with LS.
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